Navigation Links
Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
Date:11/12/2013

DURHAM, N.C., Nov. 12, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeff Abbey, president and chief executive officer, is scheduled to present at the Elsevier Therapeutic Area Partnerships Meeting on November 19 at the Hyatt Regency Boston. Event:

Elsevier Therapeutic Area Partnerships MeetingDate:

Tuesday, November 19, 2013Time:

2:55 PMLocation: 

Duxbury Room, 4th FloorHyatt Regency Boston1 Avenue De Lafayette, Boston, MA 02111Mr. Abbey will present an overview of the clinical development program for the Company's investigational fully personalized immunotherapy targeted to HIV, AGS-004, which has been designated as one of the "Top Projects to Watch" in infectious disease at the meeting. 

About the Arcelis™ Technology PlatformArcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos TherapeuticsArgos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos' most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit www.argostherapeutics.com.


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
2. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
5. Sorrento Therapeutics Adopts Stockholder Rights Plan
6. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
7. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
8. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
9. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
10. Echo Therapeutics Announces Third Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... A research report by Arcview Market Research focused on cannabis ... changing landscape of the legal market reveals that regulated cannabis sales ... , a 30% increase from 2015. According to the research ... 2021 representing a 26 percent compound annual growth rate. The use ... Canada is gradually becoming more mainstream thanks ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017  Based ... therapy market, Frost & Sullivan recognizes SnooZeal, Inc. ... SnooZeal is a highly innovative product that intelligently ... training the tongue muscles through the clinically proven ... over-the-counter (OTC) status, SnooZeal is one of the ...
(Date:2/22/2017)... Feb 22, 2017 Research and Markets ... Devices Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, ... ... Market is forecasted to grow at a CAGR of 5.33% during ... prevalence of infectious diseases along with surging demand of digital thermometer. ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... WV (PRWEB) , ... February 22, 2017 , ... ... awarded a contract to Quality Insights to help small practices in Delaware, New ... Payment Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... communications company, launched a new media platform connecting healthcare technology professionals and other ... be followed by a quarterly publication starting on March 1, announced Michael J. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued to steadily ... the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also ... the benefits of corn and grains, value of raw and organic diets, and the ...
Breaking Medicine News(10 mins):